HER2 Positive Breast Carcinoma Clinical Trials

34 clinical trials for HER2 Positive Breast Carcinoma across international registries, including 6 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer — RECRUITING
• Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk — RECRUITING
• Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy — RECRUITING · NA
• AI-based pCR Assessment/Prediction in HER2-Positive BC Using PET/MRI — RECRUITING
• RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 Study — RECRUITING
• Validation of TAD in HER-2 with More Than 2 Lymph Nodes — RECRUITING
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations — ACTIVE_NOT_RECRUITING · PHASE2
• Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery — COMPLETED · PHASE2
• TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer — COMPLETED · PHASE2
• Circulating Tumor DNA Based Minimal Residual Disease Detection for Patients With Early-Stage Breast Cancer — WITHDRAWN · NA
• Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial — ACTIVE_NOT_RECRUITING · PHASE1
• T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial — ACTIVE_NOT_RECRUITING · PHASE3
• HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer — COMPLETED · PHASE1
• Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer — TERMINATED · PHASE1
• Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer — TERMINATED · PHASE2
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer — COMPLETED · PHASE3
• Predictive Value of Tumor Vascular Normalization Scoring in HER-2 Positive Breast Cancer — ACTIVE_NOT_RECRUITING
• Nipple Aspirate Fluid in Detecting Breast Cancer — COMPLETED · NA
• T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer — COMPLETED · PHASE2
• Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer — SUSPENDED · PHASE1
• A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases — OTHER · PHASE2
• Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer — COMPLETED · PHASE2
• Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer — COMPLETED · PHASE2
• 4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer — COMPLETED · PHASE1
• T-DM1 With or Without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer — WITHDRAWN · PHASE2
• Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 — TERMINATED · PHASE2
• Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer — COMPLETED · PHASE3
• Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer — COMPLETED · PHASE2
• Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive — COMPLETED · PHASE3
• A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2 — OTHER

Refine this search